Abbott Projects Synthroid Double-Digit Growth Despite Early-2002 Phase-Down
Abbott is projecting strong growth for Synthroid in 2002 despite the phase-down of distribution required during FDA review of the NDA for the levothyroxine product
Abbott is projecting strong growth for Synthroid in 2002 despite the phase-down of distribution required during FDA review of the NDA for the levothyroxine product